GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Coloplast AS (XTER:CBHD) » Definitions » Cash Flow from Financing

Coloplast AS (XTER:CBHD) Cash Flow from Financing : €892 Mil (TTM As of Jun. 2024)


View and export this data going back to . Start your Free Trial

What is Coloplast AS Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Jun. 2024, Coloplast AS received €0 Mil more from issuing new shares than it paid to buy back shares. It received €6 Mil from issuing more debt. It paid €0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent €151 Mil paying cash dividends to shareholders. It received €0 Mil on other financial activities. In all, Coloplast AS spent €145 Mil on financial activities for the three months ended in Jun. 2024.


Coloplast AS Cash Flow from Financing Historical Data

The historical data trend for Coloplast AS's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coloplast AS Cash Flow from Financing Chart

Coloplast AS Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -497.50 -518.55 -427.11 885.58 706.00

Coloplast AS Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -87.98 867.45 -198.16 376.33 -153.55

Coloplast AS Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Coloplast AS's Cash from Financing for the fiscal year that ended in Sep. 2023 is calculated as:

Coloplast AS's Cash from Financing for the quarter that ended in Jun. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €892 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coloplast AS  (XTER:CBHD) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Coloplast AS's issuance of stock for the three months ended in Jun. 2024 was €0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Coloplast AS's repurchase of stock for the three months ended in Jun. 2024 was €0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Coloplast AS's net issuance of debt for the three months ended in Jun. 2024 was €6 Mil. Coloplast AS received €6 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Coloplast AS's net issuance of preferred for the three months ended in Jun. 2024 was €0 Mil. Coloplast AS paid €0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Coloplast AS's cash flow for dividends for the three months ended in Jun. 2024 was €-151 Mil. Coloplast AS spent €151 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Coloplast AS's other financing for the three months ended in Jun. 2024 was €0 Mil. Coloplast AS received €0 Mil on other financial activities.


Coloplast AS Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Coloplast AS's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Coloplast AS Business Description

Address
Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.

Coloplast AS Headlines

No Headlines